Biology is undergoing a structural shift. For decades, progress was driven primarily by experimentation and observation, with each study generating valuable but often isolated insights. Today, multi-omics technologies, automation, large-scale data integration, and AI are converging to make living systems increasingly computable.
In this new landscape, competitive advantage no longer depends solely on generating data, it depends on interpreting it correctly, integrating it coherently, and translating it into decisions that accelerate development and reduce risk.
Cmbio operates at the center of this transformation.
From Microbiome Pioneer to Integrated Platform
Cmbio’s origins are rooted in microbiome science. Through entities such as CosmosID and Clinical Microbiomics, the organization established itself as a leader in high-resolution microbiome profiling, advanced bioinformatics, and regulatory-ready sequencing solutions. These capabilities enabled pharmaceutical, biotech, and consumer health partners to move beyond descriptive analysis toward strain-level precision, mechanistic insight, and clinically actionable endpoints.
The acquisition of DNA Sense and the assets of Eagle Genomics marked a strategic expansion. Rather than operating as separate specialized units, the company integrated sequencing, metabolomics, bioinformatics, and systems biology into a unified operating model. Cmbio demonstrates evolution — from a collection of microbiome-focused capabilities to a comprehensive, multi-omics science partner supporting discovery through clinical validation.
Today, Cmbio provides end-to-end solutions designed to support translational programs, de-risk development pipelines, and strengthen regulatory positioning.
Digital Biology: From Data to Predictive Insight
As biological research becomes increasingly data-rich and interconnected, interpretation becomes the critical bottleneck.
Cmbio integrates short- and long-read DNA sequencing, metabolomics, transcriptomics, and multi-omics data analysis with advanced computational frameworks and applied AI. Its laboratories in Denmark and the United States are equipped with state-of-the-art LC-MS/MS and GC-MS instrumentation capable of measuring thousands of metabolites and lipids in a single sample.
These platforms support biomarker discovery, mode-of-action studies, fermentation optimization, and microbial characterization across clinical and industrial contexts.
However, the company’s differentiator lies in systems-level integration.
By combining computational science, large-scale datasets, and systems biology, Cmbio builds models that move biology from descriptive to predictive. Iteration becomes computationally accelerated rather than limited by wet-lab throughput. Hypotheses can be simulated, refined, and prioritized before validation, improving speed-to-insight and reducing experimental uncertainty.
Cmbio defines this integrated operating model as Digital Biology — a framework that transforms biological complexity into scalable, actionable evidence for product development, therapeutic innovation, and microbiome-driven applications.
Expertise Designed for Translational Impact
Cmbio’s services span the full continuum from discovery to clinical validation, including:
- Short- and long-read sequencing
- Metagenomics and strain-level microbial characterization
- Metabolomics and lipidomics
- Multi-omics integration and systems biology
- Machine learning-enabled data modeling
- Regulatory-ready data packages for microbiome endpoints
Advanced bioinformatic pipelines enable clonal-level resolution, strain tracking, engraftment analysis correlated to phenotypes, and in-silico strain screening that de-risks candidate selection and shortens development timelines.
For drug developers, this means stronger mechanistic hypotheses and more robust endpoint strategies.
For consumer health and AgBio innovators, it means clearer product differentiation and defensible claims supported by integrated biological evidence.
Cmbio operates not merely as a service provider, but as a scientific extension of its partners’ R&D organizations — connecting data streams, clarifying biological mechanisms, and strengthening decision-making at critical inflection points.
A Global Platform with Danish Foundations
While Cmbio operates internationally, Denmark remains a central pillar of its scientific infrastructure and identity. With advanced laboratories and research teams based in Denmark, the company is deeply connected to the Nordic life science ecosystem — known globally for its strength in biotechnology, sustainability, and translational science.
This Danish foundation supports Cmbio’s global footprint, which includes laboratory capabilities in both Europe and the United States. For partners operating across geographies, this dual presence provides operational flexibility, scientific continuity, and access to high-quality, scalable infrastructure.
As Cmbio participates in the Microbiome Times Partnering Forum in Copenhagen, it does so as both an international multi-omics platform and a company embedded in the local innovation landscape.
Enabling the Next Phase of Microbiome Innovation
The microbiome field is entering a new phase — one defined not only by discovery, but by translation, validation, and commercialization. Success in this environment requires more than sequencing depth or analytical breadth. It requires integration, predictive capability, and regulatory foresight.
Cmbio’s evolution — from microbiome pioneer to Digital Biology platform — reflects this broader shift. By combining advanced laboratory technologies, deep bioinformatics expertise, and systems-level integration, the company helps partners move from complex data to confident action.
At the Microbiome Times Partnering Forum, Cmbio looks forward to engaging with innovators seeking collaborative pathways to accelerate development, strengthen scientific foundations, and translate microbiome insights into scalable impact.